ALZN - MCAP CO - Alzamend Neuro, Inc.

Alzamend Neuro, Inc. (ALZN) research centers are developing therapies for psychiatric disorders and Alzheimer's disease, leveraging proprietary lithium-based developments. Capital management efficiency is ensured by outsourcing clinical trials to international third-party contractors. The business model is based on a closed patent loop for lithium delivery, and the market capitalization stands at 0.01. The company's price chart clearly illustrates the dynamics of this biotechnology sector.

Alzamend Neuro, Inc. (ALZN) leverages a unique lithium ion delivery technology that provides the company with potential pricing power within the Alzheimer's therapy market. The trend in the company's aggregate market valuation reflects investor expectations regarding this monopoly power. This figure is calculated as the product of the current share price and the total number of outstanding securities. This metric measures the current value of the entire business through the lens of market demand. Steady growth in market capitalization confirms fundamental confidence in the drug's commercialization.